ArticleJournal of clinical and experimental hematopathology : JCEH2026
Clinicopathological features of primary cold agglutinin disease in the Japanese population: Heterogeneous characteristics and diagnostic challenges.
Article in Journal of clinical and experimental hematopathology : JCEH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cold agglutinin disease (CAD) is an autoimmune hemolytic anemia triggered by exposure to cold. Primary CAD, defined as CAD not associated with malignant neoplasms or infections, has recently been recognized as a monoclonal B-cell lymphoproliferative disorder in the fifth edition of the World Health Organization Classification of Tumors: Hematolymphoid Tumors. This study aimed to clarify the clinicopathologic spectrum of primary CAD in a Japanese cohort through comprehensive clinicopathologic and molecular analyses. Twenty-one patients were clinically diagnosed with CAD, of whom eight were classified as having cold agglutinin syndrome (CAS) due to underlying conditions such as infections or neoplasms. The remaining 13 patients underwent detailed histologic and molecular evaluation and were stratified into three groups: Group 1, four patients with clinicopathologic features consistent with primary CAD; Group 2, six patients showing overlapping features with other indolent B-cell lymphomas; and Group 3, three patients in whom tumor cells were scarcely detectable histologically. Based on integrated clinicopathologic and molecular findings, nine patients (69%) were ultimately classified as having primary CAD, including all Group 1 patients, four from Group 2, and one from Group 3. These findings highlight the diagnostic challenges of primary CAD, even after exclusion of CAS-associated underlying conditions by standard clinical evaluation, and demonstrate that primary CAD encompasses a heterogeneous clinicopathologic spectrum. Our results suggest that further refinement of the current diagnostic criteria for primary CAD may be warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.